BioAlliance Pharma submits clinical trial new drug application

and announces results of its July 27th 2009 General Assembly Meeting

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the submission of a Fentanyl Lauriad® clinical trial application to the French Drug Agency (AFSSaPS) and its approval by the Ethics Committee (Comité de Protection des Personnes). This Phase I clinical trial will recruit its first subjects before end 2009. Patented until 2030, Fentanyl Lauriad® is based on the same muco-adhesive technology already validated with Loramyc®, BioAlliance already marketed drug. This sustained release new product is dedicated to the treatment of cancer chronic pain.
Furthermore, BioAlliance Pharma’s shareholders were invited to attend the Extraordinary and Ordinary General Assembly Meeting on July 27th 2009 to vote on a new governance structure with a Board of Directors and corresponding changes of the by-laws. A total of a 7,238,991 shares, representing 56.20% of existing shareholders, were attending or were represented at the Meeting. The resolution received 66.06% of the votes. As 66.67% were necessary to allow the structural changes, the current organisation of the Supervisory Board and Management Board will be maintained.

090728_Fentanyl_Lauriad_AG_2707_EN